LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib for previously treated advanced renal cell carcinoma

BACKGROUND: Immunotherapy is a standard-of-care first-line treatment for advanced clear cell renal cell carcinoma (ccRCC). However, many patients will develop resistance to first-line therapy, and effective second- and later-line treatment options are therefore needed. The von Hippel-Lindau (VHL) ge...

Descripción completa

Detalles Bibliográficos
Autores principales: McDermott, David F, Peer, Avivit, Agarwal, Neeraj, Atkins, Michael B, Cornell, Jerry, Perini, Rodolfo F, Grossmann, Kenneth F, Gurney, Howard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Trials in Progress Abstract Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445559/
http://dx.doi.org/10.1093/oncolo/oyad216.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445559/
http://dx.doi.org/10.1093/oncolo/oyad216.017

Ejemplares similares